| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2075 | 2017 |
| EASL recommendations on treatment of hepatitis C 2018 European Association for The Study of The Liver Journal of hepatology 69 (2), 461-511, 2018 | 1877* | 2018 |
| EASL recommendations on treatment of hepatitis C: final update of the series☆ JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ... Journal of hepatology 73 (5), 1170-1218, 2020 | 694 | 2020 |
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ... Liver International 31, 30-60, 2011 | 585 | 2011 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 415 | 2016 |
| Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study O Dalgard, K Bjøro, KB Hellum, B Myrvang, S Ritland, K Skaug, ... Hepatology 40 (6), 1260-1265, 2004 | 393 | 2004 |
| Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials C Axfors, AM Schmitt, P Janiaud, J Van’t Hooft, S Abd-Elsalam, EF Abdo, ... Nature communications 12 (1), 2349, 2021 | 337 | 2021 |
| CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients V Béziat, O Dalgard, T Asselah, P Halfon, P Bedossa, A Boudifa, ... European journal of immunology 42 (2), 447-457, 2012 | 322 | 2012 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 303 | 2022 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 301 | 2018 |
| Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response O Dalgard, K Bjøro, H Ring‐Larsen, E Bjornsson, M Holberg‐Petersen, ... Hepatology 47 (1), 35-42, 2008 | 259 | 2008 |
| HCV epidemiology in high-risk groups and the risk of reinfection H Midgard, A Weir, N Palmateer, VL Re III, JA Pineda, J Macías, ... Journal of hepatology 65 (1), S33-S45, 2016 | 219 | 2016 |
| Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C MS Sulkowski, C Cooper, B Hunyady, J Jia, P Ogurtsov, ... Nature reviews Gastroenterology & hepatology 8 (4), 212-223, 2011 | 215 | 2011 |
| Recommendations for the management of hepatitis C virus infection among people who inject drugs J Grebely, G Robaeys, P Bruggmann, A Aghemo, M Backmund, ... International Journal of Drug Policy 26 (10), 1028-1038, 2015 | 207 | 2015 |
| The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm–volume 2 A Hatzakis, V Chulanov, AC Gadano, C Bergin, Z Ben‐Ari, J Mossong, ... Journal of viral hepatitis 22, 26-45, 2015 | 184 | 2015 |
| IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection A Moghaddam, E Melum, N Reinton, H Ring‐Larsen, H Verbaan, K Bjøro, ... Hepatology 53 (3), 746-754, 2011 | 182 | 2011 |
| Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up O Dalgard, K Bjøro, K Hellum, B Myrvang, K Skaug, B Gutigard, H Bell European addiction research 8 (1), 45-49, 2002 | 182 | 2002 |
| Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ... The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018 | 165 | 2018 |
| Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy O Dalgard, K Bjøro, K Hellum, B Myrvang, T Bjøro, E Haug, H Bell Journal of internal medicine 251 (5), 400-406, 2002 | 161 | 2002 |
| Hepatitis C reinfection after sustained virological response H Midgard, B Bjøro, A Mæland, Z Konopski, H Kileng, JK Damås, ... Journal of hepatology 64 (5), 1020-1026, 2016 | 149 | 2016 |
